NAD+ 100mg

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in cellular energy metabolism, DNA repair, and mitochondrial function[1]. Clinical research has primarily employed intravenous infusions at high doses, though subcutaneous administration at lower doses is emerging as a practical maintenance route[2][3]. This educational protocol presents a once‑daily subcutaneous approach with gradual titration for improved tolerability.

• Reconstitute: Add 3.0 mL bacteriostatic water → 166.7 mg/mL concentration.
• Typical daily range: 50–100 mg once daily subcutaneously (gradual titration from lower doses).
• Easy measuring: At 166.7 mg/mL, 1 unit = 0.01 mL = 1.67 mg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light and avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

• Frequency: Inject once daily subcutaneously. This gradual titration protocol begins at 50 mg daily to assess tolerance, as starting too high can produce adverse reactions such as insomnia, anxiety, or fatigue[4]. Most individuals find doses in the 50–100 mg range well‑tolerated after ramp‑up[5]. The 3.0 mL dilution keeps per‑injection volumes practical and allows for accurate unit measurements on standard insulin syringes.

Reconstitution Steps

Note: Each 0.01 mL (1 unit) contains approximately 1.67 mg of NAD+. Example conversions: 50 mg = 30 units; 75 mg = 45 units; 100 mg = 60 units.

• Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
• Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
• Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
• Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously).
• The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
• Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
• Use within 14 days; inspect before each use for clarity.
• Evidence context (important): The table above is a conversion aid for a 5 mg vial reconstituted to 3.0 mL. It is not a clinical recommendation. Published MGF literature is largely preclinical (e.g., muscle and cardiocerebral models) and uses local or systemic routes distinct from subcutaneous daily regimens.[1][3][4][5][6]

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration as outlined above.

• Peptide Vials (NAD+, 500 mg each):
• Peptide Vials (NAD+, 500 mg each):: 8 weeks ≈ 11 vials (total 5,075 mg used)
• Peptide Vials (NAD+, 500 mg each):: 12 weeks ≈ 16 vials (total 7,875 mg used)
• Peptide Vials (NAD+, 500 mg each):: 16 weeks ≈ 22 vials (total 10,675 mg used)
• Insulin Syringes (U‑100, 1 mL):
• Insulin Syringes (U‑100, 1 mL):: Per week: 7 syringes (1/day)
• Insulin Syringes (U‑100, 1 mL):: 8 weeks: 56 syringes
• Insulin Syringes (U‑100, 1 mL):: 12 weeks: 84 syringes
• Insulin Syringes (U‑100, 1 mL):: 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 8 weeks (11 vials): 33 mL → 4 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 12 weeks (16 vials): 48 mL → 5 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 16 weeks (22 vials): 66 mL → 7 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily subcutaneous regimen.

• Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation[1]. Open source
• Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose titration.
• Dose Range: 50–100 mg daily; start low (50 mg) and increase by ~25 mg weekly as tolerated.
• Reconstitution: 3.0 mL per 500 mg vial (166.7 mg/mL) for accurate unit measurements.
• Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light.

Dosing Protocol

Suggested daily titration approach for subcutaneous administration.

• Start: 50 mg daily for Week 1 to assess individual tolerance.
• Escalation: Increase by 25 mg in Week 2 (75 mg daily); advance to 100 mg daily by Week 3 if well‑tolerated[4][5]. Open source
• Maintenance: Continue at 100 mg daily for Weeks 3–16 (or adjust based on response and tolerability).
• Frequency: Once per day, subcutaneous injection.
• Timing: Any consistent time of day; some users prefer morning administration.
• Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent tissue buildup.

Storage Instructions

Proper storage is critical to preserve NAD+ stability and potency.

• Lyophilized (Unopened): Store at −20 °C (−4 °F) or below (ideally −80 °C for multi‑year storage) in a dry, dark environment[6]. Minimize moisture exposure as NAD+ powder is hygroscopic. Open source
• Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within approximately 14 days[7]. Keep protected from light (UV exposure degrades NAD+). Open source
• Avoid Freeze–Thaw Cycles: Do not repeatedly freeze and thaw reconstituted NAD+ solution, as this reduces potency.
• Inspection: Before each use, inspect the solution for clarity. A fresh NAD+ solution should be clear and colorless. Discard if discoloration, cloudiness, or precipitate develops.

Important Notes

Practical considerations for consistency, safety, and optimal results.

• Use new, sterile insulin syringes for each injection; dispose of used needles in a proper sharps container.
• Rotate injection sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to reduce soreness and prevent lipohypertrophy.
• Clean both the vial stopper and injection site with alcohol swabs; allow skin to air‑dry before injecting.
• Inject slowly over 5–10 seconds to minimize tissue irritation; wait a few seconds before withdrawing the needle.
• Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
• If persistent redness or a lump develops at injection sites, apply over‑the‑counter hydrocortisone cream and rotate to a different location.
• Starting at the low end (50 mg) is recommended to assess individual tolerance before escalating dose[4]. Open source

How This Works

NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis[1]. Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience[8].

• Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500–1,000 mg) for applications such as addiction treatment and acute metabolic support[2][9]. A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was well‑tolerated in humans, with rapid metabolic clearance and no acute toxicity[10]. However, IV administration requires clinical supervision and specialized equipment.
• Subcutaneous (SC) or intramuscular (IM) injections at lower doses (tens to low hundreds of milligrams) are emerging as practical alternatives for maintenance therapy and wellness applications[3][11]. Compounded NAD+ can be administered SC in small volumes, and SC self‑injection is convenient for ongoing use[12]. Conservative protocols start around 50–100 mg per injection a few times per week; the present protocol uses daily SC administration with gradual titration to optimize individual tolerance and response.

Lifestyle Factors

Complementary strategies to maximize NAD+ therapy outcomes.

• Nutrition: Consume a balanced diet rich in NAD+ precursors (niacin/vitamin B3, tryptophan) and support nutrients (B‑vitamins, magnesium). Consider foods that support methylation pathways.
• Exercise: Regular physical activity (both resistance training and aerobic exercise) naturally upregulates cellular NAD+ biosynthesis and enhances mitochondrial adaptations.
• Sleep: Prioritize 7–9 hours of quality sleep per night to support cellular repair processes and optimize circadian NAD+ metabolism.
• Stress Management: Chronic stress depletes NAD+ pools through activation of poly(ADP‑ribose) polymerases (PARPs); incorporate stress‑reduction practices like meditation or yoga.
• Avoid Excessive Alcohol: Alcohol metabolism consumes NAD+; moderate or eliminate alcohol intake during NAD+ protocols.

Potential Benefits & Side Effects

Observations from preclinical models and clinical case reports.

• May support cellular energy production and mitochondrial function through replenishment of NAD+ pools[1][8]. Open source
• Human case reports and pilot studies suggest benefits at 100–300 mg/day ranges for cognitive support and metabolic health[13]. Open source
• High‑dose IV protocols (500–1,500 mg daily for ~10 days) have been used in open‑label studies for substance use disorder, with reports of reduced cravings and improved mood in follow‑ups[2][9]. Open source
• No severe adverse events have been reported in published NAD+/NADH trials; side effects are generally mild[14]. Open source
• High doses can produce adverse reactions such as insomnia, anxiety, or fatigue if escalated too quickly; gradual titration is advised[4]. Open source
• Mild injection‑site reactions (redness, itching, soreness) may occur with subcutaneous administration; typically resolve with site rotation.
• Some individuals report transient headache or flushing; these effects are generally dose‑dependent.
• Doses exceeding ~200–300 mg/day should generally be reserved for supervised therapeutic use due to potential for metabolic byproduct accumulation[15]. Open source

Injection Technique

General subcutaneous injection guidance based on CDC best‑practice resources and clinical literature[16][17].

• Wash hands thoroughly with soap and water.
• Clean the vial stopper with an alcohol swab and allow to air‑dry.
• Select injection site (abdomen at least 2 inches from navel, outer thigh, or back of upper arm) and clean with alcohol swab; allow skin to air‑dry completely before injecting.
• Use a fine, short needle such as a 28–31 gauge insulin syringe.
• Needle length of 5/16 to 1/2 inch (8–12 mm) is sufficient to reach subcutaneous tissue in most adults[16]. Open source
• Standard U‑100 insulin syringes (1 mL capacity) are appropriate for the volumes used in this protocol (0.30–0.60 mL per injection).
• Pinch a fold of skin between your thumb and forefinger to isolate subcutaneous tissue.
• Insert the needle at approximately a 45° angle into the pinched subcutaneous layer[16][17]. (For ultrashort 4 mm needles, a 90° angle without pinching may be used, but for typical 8–12 mm needles, 45° with pinched skin is recommended.) Open source
• Do not aspirate for subcutaneous injections[16]. Open source
• Depress the plunger slowly and steadily to inject the NAD+ solution over 5–10 seconds. Injecting too rapidly may increase irritation.
• Wait a few seconds after full injection before withdrawing the needle at the same angle it was inserted.
• Apply a clean cotton swab or bandage with light pressure to the site; do not rub vigorously.
• Dispose of the used needle/syringe immediately in a proper sharps container.
• Rotate injection sites systematically to prevent soreness, lipohypertrophy, or scar tissue buildup[18]. Open source
• Alternate between left/right sides of the abdomen or different quadrants if injecting daily.
• The abdomen (at least 2 inches away from the navel) is a common site for subcutaneous NAD+ because it has a good layer of subcutaneous fat and tends to be less sensitive.
• Outer thigh and back of upper arm are alternative sites; choose areas with adequate subcutaneous tissue.
• NAD+ injections in this protocol range from 0.30 mL (50 mg dose) to 0.60 mL (100 mg dose).
• Subcutaneous tissue can comfortably absorb up to about 1.5 mL per injection; the volumes used here are well within this limit[19]. Open source
• If higher individual doses are ever needed (above ~150 mg), consider splitting into two injections at different sites to enhance absorption and comfort.

Recommended Source

We recommend Prime Lab Peptides for high‑purity NAD+ (500 mg vials).

• High‑purity NAD+ (≥98%) with third‑party testing and batch Certificates of Analysis (COAs).
• Consistent, ISO‑aligned handling, sterile lyophilization, and comprehensive documentation.
• Reliable fulfillment with proper cold‑chain packaging to maintain product integrity during shipping.
• Transparent quality assurance and responsive customer support for research applications.
• Shop at Prime Lab Peptides

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

• Do not start, stop, combine, or change a protocol based only on website content.
• Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference-derived details for NAD+ 100mg.

• NAD+ (500mg/10mL Vial) Open source
• Pharmaceuticals (Basel) — Clinical evidence for targeting NAD+ therapeutically: metabolic pathways and therapeutic potential View Source Open source
• Current Psychiatry Research and Reviews — NAD+ and enkephalinase infusions attenuate burden in substance use disorder (pilot of 50 cases) View Source Open source
• Fagron Academy (US) — NAD+ dosing review: routes, protocols, and case study insights from clinical practice View Source Open source
• Jinfiniti (NAD+ Dosage Chart) — NAD+ injection dosage guidance: chart, timing, and safety considerations for titration View Source Open source
• Olympia Pharmacy — NAD+ injection (Nicotinamide Adenine Dinucleotide): compounding pharmacy information and dosing guidance View Source Open source
• Sigma-Aldrich Product Information — β‑Nicotinamide adenine dinucleotide (NAD+) product specification and stability data View Source Open source
• Empower Pharmacy — NAD+ injection (lyophilized): compounding specifications and reconstitution guidance View Source Open source
• PMC (Pharmacology & Potential Implications of NAD+) — Comprehensive review of NAD+ metabolism, aging, and therapeutic applications View Source Open source
• AgelessRx — NAD+ injection clinical overview and administration protocols View Source Open source
• Frontiers in Aging Neuroscience — A pilot study investigating changes in human plasma and urine NAD+ metabolome during 6‑hour IV infusion (750 mg dose) View Source Open source
• Pure Bio Labs — NAD+ vial (500 mg): high‑purity peptide product specifications View Source Open source
• Fagron Academy (NAD+ Review) — Subcutaneous and intramuscular NAD+ administration: emerging practices for maintenance therapy View Source Open source
• Jinfiniti (Dosage Chart) — Human case reports: benefits at 100–300 mg/day ranges for cognitive and metabolic support View Source Open source
• American Journal of Physiology (PubMed) — Evaluation of safety and effectiveness of NAD+ in different clinical conditions: a systematic review View Source Open source
• Fagron Academy — Dosing considerations: regimens exceeding 200–300 mg/day reserved for supervised therapeutic use View Source Open source
• CDC Pink Book (Chapter 6) — Vaccine administration: needle selection and injection technique for subcutaneous route View Source Open source
• CDC Subcutaneous Injection Guide — Technique diagram and site guidance for subcutaneous injections (45–90° angle, no aspiration) View Source Open source
• NCBI Bookshelf — Best practices for injections: asepsis, site preparation, administration, and rotation to prevent lipohypertrophy View Source Open source
• PMC (Subcutaneous Drug Injection Review) — Literature review of factors influencing pain at injection site and volume considerations for subcutaneous route View Source Open source
• Prime Lab Peptides — NAD+ 500 mg product page: quality specifications and batch documentation View Source Open source